ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4285
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,014.88
0.24%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Avadel Pharmaceuticals PLC (AVDL)

  7. Avadel Pharmaceuticals PLC (AVDL) Noticias

AVDL

Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AVDL
FechaHoraFuenteTítuloSímboloCompañía
14/11/202410:50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
13/11/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/11/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/11/202406:00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
04/11/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/10/202406:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act LitigationNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202413:02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep AdvancesNASDAQ:AVDLAvadel Pharmaceuticals PLC
17/10/202408:41GlobeNewswire Inc.Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with NarcolepsyNASDAQ:AVDLAvadel Pharmaceuticals PLC
25/09/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting AgentNASDAQ:AVDLAvadel Pharmaceuticals PLC
16/09/202416:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
03/09/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)NASDAQ:AVDLAvadel Pharmaceuticals PLC
28/08/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:AVDLAvadel Pharmaceuticals PLC
20/08/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral SuspensionNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202408:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202406:00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/07/202415:05GlobeNewswire Inc.Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic HypersomniaNASDAQ:AVDLAvadel Pharmaceuticals PLC
27/06/202415:05GlobeNewswire Inc.Avadel Pharmaceuticals to Join Russell 3000® IndexNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202406:25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202406:17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202406:11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AVDLAvadel Pharmaceuticals PLC
22/05/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024NASDAQ:AVDLAvadel Pharmaceuticals PLC
21/05/202416:27Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
21/05/202406:00GlobeNewswire Inc.Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of DirectorsNASDAQ:AVDLAvadel Pharmaceuticals PLC
17/05/202415:18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/05/202415:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AVDLAvadel Pharmaceuticals PLC
08/05/202407:29IH Market NewsU.S. Futures Slightly Dip Amid Corporate Earnings and Quiet Economic Calendar, Oil Prices FallNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/05/202406:00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/05/202407:00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8NASDAQ:AVDLAvadel Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:AVDL

Su Consulta Reciente

USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
CCOM
SILVER
SILVER
COIN
XRPUSD
Ripple
COIN
ADAUSD
Cardano
NYSE
BAC
Bank of America
AMEX
XLV
Health Care Select Sector
USOTC
ADDYY
Adidas (QX)
COIN
SOLUSD
Solana
NASDAQ
MSFT
Microsoft
FX
EURMXN
Euro vs MXN
CCOM
OILBRENT
Brent Oil
COIN
BTCUSD
Bitcoin
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados